BMBárbara Martins

Bárbara Martins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bárbara Martins has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Subjective cognitive symptoms improve following effective migraine treatment: A patient‐reported outcome study

    by Mariana Costa Taveira, Filipa Dourado Sotero, João Nobre, Mariana Dias da Costa, Rita Rato, Andreia Costa, Bárbara Martins, Maria Roque, Isabel Pavão Martins

    Objectives/Background: Our objective was to investigate whether subjective cognitive symptoms improve after effective preventive migraine treatment. Subjective cognitive symptoms, such as memory and concentration difficulties, are increasingly recognized as part of the clinical spectrum of migraine. We aimed to evaluate whether subjective cognitive symptoms improve with effective preventive migraine treatment acting predominantly outside the central nervous system. Methods: We conducted a prospective two‐center observational cohort study with a pre–post (within‐person) design including adults with migraine diagnosed according to the International Classification of Headache Disorders, 3rd edition criteria, who initiated preventive treatment with either anti‐calcitonin gene‐related peptide/calcitonin gene‐related peptide receptor monoclonal antibodies or onabotulinumtoxinA at two tertiary headache centers in Portugal between October 2023 and August 2025. Treatment response was defined as a ≥50% reduction in monthly moderate to severe headache days in patients with episodic migraine and a ≥30% reduction in those with chronic migraine, assessed between baseline and 3–6 months of follow‐up. Subjective cognitive symptoms, assessed using the Subjective Memory Complaints scale, and depression and anxiety symptoms, evaluated with the Hospital Anxiety and Depression Scale, were compared between baseline and follow‐up according to treatment responder status. Results: Participants ( N = 96, mean age 42.4±12.0 years, 94/96 [98%] women, 68/96 [71%] with chronic migraine), received either anti‐calcitonin gene‐related peptide/receptor monoclonal antibodies ( n = 65) or onabotulinumtoxinA ( n = 31), and 51 responded to treatment. Treatment responders showed greater improvement in subjective cognitive symptoms than nonresponders ( B = −2.22, 95% CI = −3.62 to −0.82, p = 0.002), regardless of preventive treatment type ( B = 0.17, 95% CI = −1.34 to 1.68, p = 0.825) and baseline depression ( B = 0.02, 95% CI = −0.21 to 0.24, p = 0.894) and anxiety ( B = −0.06, 95% CI = −0.25 to 0.13, p = 0.545) symptoms. Although in patients with borderline or clinically significant depression symptoms, cognitive improvement was primarily associated with improvement in depression symptoms ( B = 0.35, 95% CI = 0.03–0.68, p = 0.033; B = 0.61, 95% CI = 0.32–0.90, p < 0.001; respectively), among patients without baseline depression symptoms, cognitive improvement was only associated with treatment response ( B = −1.77, 95% CI = −3.32 to −0.21, p = 0.027). Conclusion: This study shows that effective preventive treatment is associated with significant improvement in subjective cognitive symptoms, highlighting their responsiveness to treatment and relevance to patient‐reported outcomes. image

  • Open Access

    Beyond headache: Cognitive improvement in patients with migraine responding to anti-CGRP monoclonal antibodies or botulinum toxin

    by Isabel Pavão Martins, Mariana Costa Taveira, Maria Couto, Sofia Velasco, Rita Rato, Andreia Costa, Bárbara Martins, Filipa Dourado Sotero

    Background: Cognitive functioning worsens during migraine attacks and in the interictal period, especially in chronic migraine. This study aims to evaluate whether preventive treatment with anti-CGRP monoclonal antibodies (mAbs) or botulinum toxin (BoNT) improves interictal cognitive performance in migraine patients, and to compare cognitive changes between treatment responders and non-responders, controlling for treatment type. Methods: A two-center prospective longitudinal comparative study of patients with Episodic (EM) or Chronic (CM) migraine receiving either mAbs or BoNT. Participants underwent two comprehensive cognitive evaluations targeting attention/processing speed, executive functions, episodic memory, and language, at baseline (visit 1) and after three to six months of treatment (visit 2). The primary end point was the degree of improvement measured by the z scores of each cognitive domain (adjusted for age and education), from baseline to follow-up, assessed using repeated-measures analysis with time as the within-subject factor and treatment response as the between-subject factor, controlling for treatment group. Treatment response was defined as a decrease in monthly moderate-to-severe headache days of ≥30% in CM or ≥50% in EM at follow-up. Results: One hundred patients were included, and 90 completed the study (median age = 42 years, 96.7% women, 58 (64.4%) with CM, 64 (71.1%) treated with mAbs, and 26 (28.8%) with BoNT. Forty-seven (52.2%) were responders (59.4% in the mAbs group and 34.6% in the BoNT group) after a mean follow-up time of 4.5 months. Improvement in a measure of executive functions (comprising tests of working memory, alternating attention, and phonological fluency) was significantly higher in responders than in non-responders, independently of treatment group. No significant differences between responders and non-responders were observed in episodic memory, language, or processing speed. Among responders, the change in executive function score was not associated with the reduction in monthly moderate-severe headache days or the final number of monthly headache-free days. Conclusions: Performance on measures of executive capacities, may improve in migraine patients after a few months of effective migraine treatment with mAbs or BoNT, regardless of the treatment group. Further research is needed to determine whether this effect augments over time, is associated to the reduction of pre-ictal and post-ictal days and /or to brain networks reorganization.


  • Open Access

    Biomarcadores Sanguíneos em Doença de Alzheimer: Ponto de Situação e Considerações Práticas

    by Rui Araújo, Bárbara Martins, Ana Sardoeira, Ana Gouveia

    A doença de Alzheimer é entendida hoje como uma entidade clínico-biológica cuja caracterização deverá levar em conta a utilização de biomarcadores. Até recentemente, o uso de biomarcadores obrigava a realização de punção lombar ou à realização de PET. O surgimento de biomarcadores sanguíneos torna mais acessível a caracterização biológica da doença e é tido como um dos principais avanços na doença de Alzheimer. A sua utilização, contudo, deve ser criteriosa porque a sua interpretação pode ser difícil, sobretudo para a população geral, e o seu valor varia substancialmente mediante a população em que é usado. Nesta revisão narrativa, apresentamos o estado da arte dos biomarcadores de sangue na doença de Alzheimer, especificamente dados de investigação recente e aplicabilidade clínica.

  • Open Access

    The Impact of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies on Sleep Quality and Daytime Sleepiness in Migraine Patients: A Multicenter Study

    by Rita Cagigal, Ângelo Fonseca, Bárbara Martins, Catarina Fernandes, Sandra Palma, Carolina Guerreiro, Carla Morgado, Diana Valente, Miguel Miranda, Joana Silva, et al.

    Purpose: This study aimed to determine whether patients with migraine experience improvements in self-reported sleep quality and daytime sleepiness after starting monoclonal antibody (mAb) therapy targeting the calcitonin gene-related peptide (CGRP) or its receptor, and to explore the association between treatment efficacy and improvements in sleep quality.Methods: This prospective, multicenter, observational, longitudinal study was conducted across 12 headache centers. Adults with episodic or chronic migraine who began anti-CGRP mAb therapy were assessed at baseline, 3 months, and 6 months. Sleep quality and daytime sleepiness were evaluated using the Portuguese version of the Pittsburgh Sleep Quality Index (PSQI-PT) and the Portuguese version of the Epworth Sleepiness Scale (ESS-PT), respectively. Results: Of 118 enrolled patients, 109 completed the study (86.4% female; mean age, 43.6 years). A significant improvement in sleep quality was observed, with median PSQI-PT scores decreasing from 9 at baseline to 6 at 6 months (p<0.001). Daytime sleepiness also improved, with median ESS-PT scores decreasing from 7 to 6 (p=0.04). Migraine frequency decreased significantly, from a median of 13 to 4 monthly migraine days (p<0.001). Greater migraine improvement was independently associated with greater PSQI-PT improvement (p<0.001), whereas changes in ESS-PT were not correlated with treatment efficacy.Conclusion: Anti-CGRP mAb therapy was associated with significant improvements in sleep quality, likely mediated through migraine relief. Changes in ESS-PT were not correlated with treatment efficacy, suggesting a possible interaction between migraine mechanisms and CGRP-mediated sleep–wake regulation. Future research should focus on clarifying the mechanisms underlying these associations.


  • Open Access

    Non-Alcohol-Related Wernicke Encephalopathy

    by Rita Nunes Rato, Bárbara Martins, Carolina Correia, Carolina Soares, Andreia Costa

    A 39-year-old male with a recent diagnosis of human immunodeficiency virus infection, in the AIDS stage, and Burkitt lymphoma, both identified in the context of a constitutional syndrome with six months of evolution developed an acute condition with psychomotor slowing, disorientation, and gait imbalance, six weeks after initiating antiretroviral therapy and chemotherapy. Neurological examination revealed multidirectional nystagmus, length-dependent sensory disturbance, and severe appendicular and gait ataxia. Brain MRI showed symmetrical hyperintensity in the medial thalami, extending to the posterior midbrain, pons, and medulla. With a clinical suspicion of Wernicke’s encephalopathy, high-dose intravenous thiamine supplementation was initiated, resulting in rapid clinical improvement and imaging regression of the lesions. This case highlights an atypical and potentially reversible presentation of Wernicke’s encephalopathy, underscoring the importance of clinical suspicion in patients with severe cachexia, hematologic malignancies, or other conditions that impair thiamine absorption.

  • Ptosis in human immunodeficiency virus-infected patients under long-term antiretroviral treatment

    by Cláudia Santos Silva, Beatriz Nunes Vicente, Bárbara Martins, Ana Cláudia Fonseca, Pedro Coelho, Rafael Roque, Fábio Cota de Medeiros, Miguel Oliveira Santos, Mamede de Carvalho


  • Open Access

    Abordagem Diagnóstica, Terapêutica e de Monitorização na Suspeita de Neurossífilis: Proposta de Protocolo Clínico

    by Bárbara Martins, Gabriela Canelas, Rafael Dias, Beatriz Prista-Leão, Cláudio Silva, Andreia Costa, André Silva-Pinto

    O presente protocolo clínico foi desenhado para servir como um guia hospitalar na abordagem diagnóstica, terapêutica e de monitorização da neurossífilis, tendo em conta a positividade ou não para o vírus de imunodeficiência humana. A sífilis é uma doença sexualmente transmissível, de notificação obrigatória, conhecida como a grande imitadora nosológica. Em cerca de 30% dos casos de doença não tratada ocorre infeção persistente do sistema nervoso central. A neurossífilis é uma forma grave e progressiva de sífilis, que pode ocorrer em qualquer estádio da doença, com frequente atraso no diagnóstico e tratamento. Classifica-se como neurossífilis precoce (meningite sifilítica, neurossífilis meningovascular ou gomas sifilíticas) e neurossífilis tardia (gomas sifilíticas, demência sifilítica ou tabes dorsalis). A importância da punção lombar prende-se não só com questões diagnósticas, mas também com a avaliação da eficácia do tratamento. O tratamento desta patologia em todos os estádios consiste em penicilina por via parentérica. Com este protocolo pretende-se facilitar a decisão clínica nos casos de suspeita de neurossífilis através de uma conduta sistematizada, individualizada e multidisciplinar.

  • Open Access

    Persistent headache attributed to past cervicocephalic artery dissection: clinical characteristics and contributors to headache persistence

    by Bárbara Pinto Martins, Inês Mesquita, José Maria Sousa, Pedro Abreu, Andreia Costa

    Background: Persistent headache/facial/neck pain attributed to past cervicocephalic arterial dissection is under-documented in literature. Our main goal was to evaluate clinical characteristics and contributors to this persistence. Methods: A retrospective cohort study which included patients with a radiologically confirmed cervicocephalic arterial dissection (2015–2020) in a Portuguese tertiary hospital. Headache persistence was identified through clinical records. A questionnaire aimed to characterize headache in three moments: previous, persistent, and headache at the time of the interview (on average 2.5 years post-event). Results: Ninety-two patients were identified; 24 (26.1%) had headache persistence ≥3 months, and 20 (22.2%) on average after 2.5 years post-event. There were no differences regarding demographics and vascular risk factors among patients with (n = 22) and without (n = 68) headache persistence. The first group had higher previous headache history (68.2% vs 4.4%, p < 0.001), delay in diagnosis (3.6 vs 1.9 days, p < 0.001), and headache/cervicalgia as the first symptom (81.8% vs 41.2%, p < 0.001). At the time of the interview, 20% still reported daily headache. A logistic regression model depicted headache history (OR = 59.8, p < 0.001), acute headache/cervicalgia (odds ratio, OR = 25.4, p = 0.005), posterior circulation dissection (OR = 7.6, p < 0.001), and less than 4 points by National Institutes of Health Stroke Scale score (OR = 5.0, p = 0.025) as contributors to headache persistence. Conclusion: Headache persistence post-cervicocephalic arterial dissection is common, and frequently affects patients daily. As it potentially affects functional outcomes and quality of life, the contributors identified in this study may help clinicians manage patients after the acute event.